- Home
- RERE vs RGNX Comparison
RERE vs RGNX Comparison
Compare RERE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- RGNX
- Stock Information
- Founded
- RERE 2011
- RGNX 2008
- Country
- RERE China
- RGNX United States
- Employees
- RERE N/A
- RGNX N/A
- Industry
- RERE Other Specialty Stores
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RERE Consumer Discretionary
- RGNX Health Care
- Exchange
- RERE Nasdaq
- RGNX Nasdaq
- Market Cap
- RERE 444.1M
- RGNX 387.0M
- IPO Year
- RERE 2021
- RGNX 2015
- Fundamental
- Price
- RERE $2.58
- RGNX $8.85
- Analyst Decision
- RERE
- RGNX Strong Buy
- Analyst Count
- RERE 0
- RGNX 8
- Target Price
- RERE N/A
- RGNX $31.75
- AVG Volume (30 Days)
- RERE 847.7K
- RGNX 1.3M
- Earning Date
- RERE 05-20-2025
- RGNX 05-12-2025
- Dividend Yield
- RERE N/A
- RGNX N/A
- EPS Growth
- RERE N/A
- RGNX N/A
- EPS
- RERE 0.07
- RGNX N/A
- Revenue
- RERE $2,388,301,386.00
- RGNX $156,718,000.00
- Revenue This Year
- RERE $29.57
- RGNX $313.52
- Revenue Next Year
- RERE $24.43
- RGNX N/A
- P/E Ratio
- RERE $35.61
- RGNX N/A
- Revenue Growth
- RERE 26.09
- RGNX 80.70
- 52 Week Low
- RERE $2.00
- RGNX $5.04
- 52 Week High
- RERE $3.70
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- RERE 48.53
- RGNX 51.64
- Support Level
- RERE $2.45
- RGNX $7.68
- Resistance Level
- RERE $2.95
- RGNX $9.29
- Average True Range (ATR)
- RERE 0.15
- RGNX 0.85
- MACD
- RERE -0.01
- RGNX -0.08
- Stochastic Oscillator
- RERE 25.00
- RGNX 43.42
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.